# Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

> **NCT02371980** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 1106 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Vortioxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02371980
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-10
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-04-25
- **Target enrollment:** 1106 (ACTUAL)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02371980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02371980, "Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02371980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*